KNSA vs. ANAB
KNSA (Kiniksa Pharmaceuticals, Ltd.) and ANAB (AnaptysBio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, KNSA returned 37.13%/yr vs 28.35%/yr for ANAB. Their 0.30 correlation means their historical movements had little consistent relationship.
Performance
KNSA vs. ANAB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 80.22% return, which is significantly higher than ANAB's 65.10% return.
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
ANAB
- 1D
- -3.05%
- 1M
- -18.45%
- 6M
- 68.83%
- YTD
- 65.10%
- 1Y
- 226.03%
- 3Y*
- 57.31%
- 5Y*
- 28.35%
- 10Y*
- —
- ALL TIME*
- 18.45%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
ANAB AnaptysBio, Inc. | $39.97M | $46.98M | $40.05M |
| $68.75M | $54.52M | $46.86M |
KNSA vs. ANAB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
ANAB AnaptysBio, Inc. | 65.10% | 266.16% | -38.19% | -30.88% | -10.82% | 61.63% | 32.31% | -74.53% | -22.19% |
Correlation
The correlation between KNSA and ANAB is 0.26, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.26 |
Correlation (3Y) Balances recent behavior with more history. | 0.28 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.34 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.30 |
Fundamentals
KNSA:
$5.67B
ANAB:
$2.30B
KNSA:
$1.00
ANAB:
-$0.90
KNSA:
7.14
ANAB:
6.82
KNSA:
9.48
ANAB:
120.10
KNSA:
$840.85M
ANAB:
$232.39M
KNSA:
$546.22M
ANAB:
$245.59M
KNSA:
$111.62M
ANAB:
$52.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. ANAB — Risk / Return Rank
KNSA
ANAB
KNSA vs. ANAB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and AnaptysBio, Inc. (ANAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KNSA | ANAB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.15 | ||
| Sortino ratioReturn per unit of downside risk | +0.82 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.45 | +0.07 |
| Calmar ratioReturn relative to maximum drawdown | 6.94 | 8.14 | -1.20 |
| Martin ratioReturn relative to average drawdown | 24.13 | 19.84 | +4.29 |
Loading charts...
Drawdowns
KNSA vs. ANAB - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, smaller than the maximum ANAB drawdown of -92.08%. Use the drawdown chart below to compare losses from any high point for KNSA and ANAB.
Loading charts...
Drawdown Indicators
| KNSA | ANAB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -92.08% | +9.02% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -27.96% | +6.84% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | -69.32% | +35.18% |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | -69.32% | +16.15% |
Current DrawdownCurrent decline from peak | -8.13% | -37.74% | +29.61% |
Average DrawdownAverage peak-to-trough decline | -40.09% | -64.17% | +24.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.06% | 11.45% | -5.39% |
Volatility
KNSA vs. ANAB - Volatility Comparison
Kiniksa Pharmaceuticals, Ltd. (KNSA) and AnaptysBio, Inc. (ANAB) have volatilities of 26.47% and 27.46%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | ANAB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.47% | 27.46% | -0.99% |
Volatility (6M)Calculated over the trailing 6-month period | 41.55% | 51.26% | -9.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.77% | 73.55% | -23.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.77% | 66.36% | -11.59% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.34% | 75.51% | -11.17% |
Dividends
KNSA vs. ANAB - Dividend Comparison
Neither KNSA nor ANAB has paid dividends to shareholders.
Financials
KNSA vs. ANAB - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and AnaptysBio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
KNSA and ANAB have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ANAB has higher volatility (27.46%) compared to KNSA (26.47%). In terms of maximum drawdown, KNSA dropped -83.06% vs ANAB's -92.08%.
ANAB currently has the higher Sharpe Ratio (3.10 vs 2.94), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and ANAB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer